{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:26:53Z","timestamp":1793064413838,"version":"4.5.0"},"reference-count":37,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Around 33% of patients treated by EBRT or brachytherapy will present a biochemical recurrence. SBRT is a new option for the treatment of patients with local-only recurrence. MRgRT seems to be interesting for the treatment of these recurrences. This article presents the one-year late tolerance and biochemical recurrence-free survival results of a prospective registry study. Patients with intraprostatic (or in the prostate bed) recurrence were treated with 5 to 9 fractions (median dose of 30 Gy in 5 fractions) with the MRIdian\u00ae system. PSA level and toxicities were evaluated before treatment and at three, six and 12 months after treatment. Thirty-seven patients with a median age of 74.5 years old were treated between 21 October 2019 and 7 December 2020. Acute tolerance was excellent with no grade &gt;2 toxicities. Twelve months after treatment, we observed an increase of grade 1\u20132 dysuria (46% vs. 13% before treatment) and grade 1 polyuria (73% vs. 7%). The six, nine and 12-months biochemical-recurrence free survival were 97.3%, 86.5% and 65.0%. Fifteen patients (40%) presented a biochemical recurrence. Nine of these 15 patients (60%) had a persistent disease within the treated volume. In conclusion, MRgRT is safe and has promising survival results.<\/jats:p>","DOI":"10.3390\/cancers14081943","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T21:15:35Z","timestamp":1649798135000},"page":"1943","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Magnetic Resonance-Guided Reirradiation for Local Recurrence within the Prostate or in the Prostate Bed: One-Year Clinical Results of a Prospective Registry Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6302-825X","authenticated-orcid":false,"given":"Morgan","family":"Michalet","sequence":"first","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-5655","authenticated-orcid":false,"given":"Olivier","family":"Riou","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Cottet-Moine","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Castan","sequence":"additional","affiliation":[{"name":"Biometrics Unit ICM, Montpellier Cancer Institute, University Montpellier, 34090 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9839","authenticated-orcid":false,"given":"Sophie","family":"Gourgou","sequence":"additional","affiliation":[{"name":"Biometrics Unit ICM, Montpellier Cancer Institute, University Montpellier, 34090 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Valdenaire","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Debuire","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Ailleres","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Draghici","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Charissoux","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Llacer Moscardo","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Farcy-Jacquet","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie du Gard, University Federation of Radiation Oncology of Mediterranean Occitanie, CHU Car\u00e9meau, 30900 N\u00eemes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Fenoglietto","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Azria","sequence":"additional","affiliation":[{"name":"Montpellier Cancer Institute, University Federation of Radiation Oncology of Mediterranean Occitanie, University Montpellier, INSERM U1194 IRCM, 34298 Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.adro.2019.01.004","article-title":"Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States","volume":"4","author":"Scherzer","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_2","unstructured":"Nombre de patients trait\u00e9s par radioth\u00e9rapie en fonction de la localisation [Internet] (2022, February 25). Available online: http:\/\/lesdonnees.e-cancer.fr\/Fiches-Indicateurs\/Prise-en-charge\/RadioT\/Nombre-de-patients-traites-par-radiotherapie-en-fonction-de-la-localisation#sources."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cncr.23161","article-title":"Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment failure after primary and salvage therapy for prostate cancer: Likelihood, patterns of care, and outcomes","volume":"112","author":"Agarwal","year":"2008","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.euo.2020.01.002","article-title":"Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy","volume":"4","author":"Jansen","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): A randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)","volume":"80","author":"Valle","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2012.01.022","article-title":"Cancer Control and Functional Outcomes of Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Systematic Review of the Literature","volume":"61","author":"Chade","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2010.12.012","article-title":"Disease-Free Survival Following Salvage Cryotherapy for Biopsy-Proven Radio-Recurrent Prostate Cancer","volume":"60","author":"Williams","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bju.13766","article-title":"Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients","volume":"119","author":"Crouzet","year":"2017","journal-title":"Br. J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.semradonc.2014.02.008","article-title":"The ViewRay System: Magnetic Resonance\u2013Guided and Controlled Radiotherapy","volume":"24","author":"Mutic","year":"2014","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.3389\/fonc.2020.616291","article-title":"MR-Guided Radiotherapy for Prostate Cancer","volume":"10","author":"Tocco","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100748","DOI":"10.1016\/j.adro.2021.100748","article-title":"Magnetic Resonance\u2013Guided Reirradiation for Local Recurrence Within the Prostate or in the Prostate Bed: Preliminary Results of a Prospective Registry Study","volume":"6","author":"Michalet","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.canrad.2019.07.125","article-title":"Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How?","volume":"23","author":"Baty","year":"2019","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clon.2017.11.007","article-title":"Robotic Stereotactic Retreatment for Biochemical Control in Previously Irradiated Patients Affected by Recurrent Prostate Cancer","volume":"30","author":"Loi","year":"2018","journal-title":"Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-017-0833-9","article-title":"Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: Preliminary results of the Oscar Lambret Center","volume":"12","author":"Leroy","year":"2017","journal-title":"Radiat. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"20180494","DOI":"10.1259\/bjr.20180494","article-title":"Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)","volume":"92","author":"Rojas","year":"2019","journal-title":"Br. J. Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"681448","DOI":"10.3389\/fonc.2021.681448","article-title":"Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review","volume":"11","author":"Zhong","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijrobp.2019.10.014","article-title":"Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT","volume":"106","author":"Fuller","year":"2019","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00066-020-01628-6","article-title":"Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer","volume":"196","author":"Cuccia","year":"2020","journal-title":"Strahlenther. Onkol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4149\/neo_2020_200622N651","article-title":"Partial prostate re-irradiation for the treatment of isolated local recurrence of prostate cancer in patients previously treated with primary external beam radiotherapy: Short-term results of a monocentric study","volume":"68","author":"Matrone","year":"2021","journal-title":"Neoplasma"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Caroli, P., Colangione, S.P., De Giorgi, U., Ghigi, G., Celli, M., Scarpi, E., Monti, M., Di Iorio, V., Sarnelli, A., and Paganelli, G. (2020). 68Ga-PSMA-11 PET\/CT-Guided Stereotactic Body Radiation Therapy Retreatment in Prostate Cancer Patients with PSA Failure after Salvage Radiotherapy. Biomedicines, 8.","DOI":"10.3390\/biomedicines8120536"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2020.07.014","article-title":"Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer","volume":"108","author":"Bergamin","year":"2020","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ijrobp.2019.02.041","article-title":"Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy","volume":"104","author":"Mancosu","year":"2019","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijrobp.2019.07.012","article-title":"Salvage Stereotactic Body Radiation Therapy for Local Prostate Cancer Recurrence After Radiation Therapy: A Retrospective Multicenter Study of the GETUG","volume":"105","author":"Pasquier","year":"2019","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_26","first-page":"20180027","article-title":"Stereotactic prostate focal reirradiation therapy for local recurrence: Preliminary results of Hartmann Oncology Radiotherapy Group","volume":"1","author":"Scher","year":"2019","journal-title":"BJR Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.brachy.2017.07.013","article-title":"Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time","volume":"16","author":"Kollmeier","year":"2017","journal-title":"Brachytherapy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.radonc.2016.04.032","article-title":"Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure","volume":"119","author":"Wojcieszek","year":"2016","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_29","first-page":"105","article-title":"HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer","volume":"1","author":"Garmol","year":"2009","journal-title":"J. Contemp. Brachytherapy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e026666","DOI":"10.1136\/bmjopen-2018-026666","article-title":"GETUG-AFU 31: A phase I\/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy\u2014study protocol","volume":"9","author":"Pasquier","year":"2019","journal-title":"BMJ Open"},{"key":"ref_31","first-page":"98","article-title":"Technical design and concept of a 0.35 T MR-Linac","volume":"18","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijrobp.2013.01.027","article-title":"Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes","volume":"86","author":"Chen","year":"2013","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1177\/1533034617741797","article-title":"Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients with Radiorecurrent Prostate Cancer","volume":"16","author":"Maenhout","year":"2017","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ijrobp.2018.06.039","article-title":"Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results from a Prospective Clinical Trial","volume":"102","author":"Murgic","year":"2018","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_35","first-page":"165","article-title":"Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure","volume":"190","author":"Walasek","year":"2013","journal-title":"Strahlenther. und Onkol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.radonc.2014.06.013","article-title":"Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: A retrospective study regarding toxicity, biochemical outcome and quality of life","volume":"112","author":"Peters","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"102206","DOI":"10.1016\/j.ctrv.2021.102206","article-title":"Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus","volume":"98","author":"Marvaso","year":"2021","journal-title":"Cancer Treat. Rev."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/8\/1943\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:52:36Z","timestamp":1760136756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/8\/1943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":37,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["cancers14081943"],"URL":"https:\/\/doi.org\/10.3390\/cancers14081943","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]}}}